You are here
Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms
Guglielmelli P, Bartalucci N, Rotunno G, Vannucchi AM
Expert Rev Hematol. 2014 May 22:1-3. [Epub ahead of print]
The recent discovery of mutations of the gene calreticulin has allowed raising the proportion of patients with essential thrombocythemia and primary myelofibrosis with known mutational abnormality up to 85-90%. Knowledge of the mechanisms by which mutated calreticulin underlie a myeloproliferative neoplasm as well as the clinical and therapeutic implications is just at the very beginning, and exciting times await research in this field.